Artelo biosciences announces publication of new peer-reviewed pre-clinical research demonstrating art26.12's effectiveness in treating and preventing oxaliplatin-induced peripheral neuropathy

Solana beach, calif., jan. 23, 2024 (globe newswire) -- artelo biosciences, inc.  (nasdaq: artl) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced new research published in the peer-reviewed journal of pain. the research article, titled “discovery and preclinical evaluation of a novel inhibitor of fabp5, art26.12, effective in oxaliplatin-induced peripheral neuropathy,” highlights artelo's pre-clinical asset, art26.12, and its potential ability to treat and prevent oxaliplatin-induced peripheral neuropathy (oipn) in a series of separate studies.
ARTL Ratings Summary
ARTL Quant Ranking